Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, announced that Nuvaxovid&tra...
After four years of follow-up, KEYTRUDA plus LENVIMA reduced the risk of death by 21% versus sunitinib in the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581...
According to the World Health Organization, Acinetobacter species top the list of critical bacterial pathogens that pose the greatest threat to human ...
AIDS Healthcare Foundation (AHF), the world’s largest HIV and AIDS healthcare organization, is seeing a reemergence of monkeypox (now known as mpox) ...
Research in MPS IVA led by REGENXBIO scientists moving into clinic Donation of NAV® Technology licenses will support development...
The first diagnostic test for long COVID is now available to patients across Australia. The test can help physicians diagnose long COVID by differentiating...
The NDA is based on the results of the Phase 3 Clarity AD study and the Phase 2b clinical study, which demonstrated that lecanemab treatment showed a reduc...
The collaboration agreement combines Angelini Pharma’s expertise in neurological diseases with JCR Pharmaceuticals’ scientific and technologi...
"Hot flashes as a result of menopause can be a serious physical burden on women and impact their quality of life," said Janet Maynard, M.D., M.H.S., direct...
Under the terms of the agreement, Aligos and Amoytop will collaborate on the research and development of oligonucleotide compounds for the treatment of liv...
UCB's expertise in macrocyclic peptide discovery, using its proprietary mRNA-display platform, ExtremeDiversity™, will aid Ariceum's discovery of t...
On March 31, 2023, the government of the Hong Kong Special Administrative Region announced that, from April 20, high-risk groups will be able to receive fr...
Increasing localized access can provide faster results for patients while potentially improving patient outcomes Agreement aims to enable greater access...
Under the terms of the agreement, Acorda will receive an up-front payment of $2.5 million, a near term milestone payment of up to $6 million, $3 million up...
© 2024 Biopharma Boardroom. All Rights Reserved.
